Table 3.

Grade ≥3 AEs (≥3% incidence in either arm) in the safety population, by receipt of induction chemotherapy.

	With induction therapy		Without induction therapy
	Pertuzumab plus trastuzumab arm	Trastuzumab arm	Pertuzumab plus trastuzumab arm	Trastuzumab arm
Patients, n (%)	(n = 74)	(n = 69)	(n = 53)	(n = 55)
Hypertension	14 (18.9)	8 (11.6)	1 (1.9)	5 (9.1)
Diarrhea	9 (12.2)	3 (4.3)	3 (5.7)	—
Anemia	4 (5.4)	3 (4.3)	2 (3.8)	—
Pneumonia	4 (5.4)	1 (1.4)	2 (3.8)	—
Asthenia	4 (5.4)	4 (5.8)	—	—
Febrile neutropenia	4 (5.4)	2 (2.9)	—	—
Left ventricular dysfunction	1 (1.4)	—	3 (5.7)	1 (1.8)
Neutropenia	4 (5.4)	8 (11.6)	—	1 (1.8)